Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer
IntroductionThe Coronavirus Disease 2019 (COVID-19) pandemic posed critical challenges in providing care to ovarian cancer (OC) patients, including delays in OC diagnosis and treatment initiation. To accommodate for delays in OC surgery, the Society of Gynecologic Oncology (SGO) recommended preferen...
Main Authors: | Amrita Mukherjee, Natalie Shammas, Lanfang Xu, Kimberly L. Cannavale, Alec D. Gilfillan, Elizabeth A. Szamreta, Matthew Monberg, Melissa Hodeib, Chun R. Chao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1290719/full |
Similar Items
-
Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer
by: Sung Jun Ma, et al.
Published: (2022-01-01) -
Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study
by: Jie Yang, et al.
Published: (2024-04-01) -
Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: Alimoghadam K, et al.
Published: (2004-07-01) -
NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
by: A. E. Solopova, et al.
Published: (2016-09-01) -
The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
by: Škof Erik, et al.
Published: (2016-09-01)